UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1618, 2024

NOTABLE LABS, LTD.

(Exact name of registrant as specified in charter)

Israel	001-36581	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
320 Hatch Drive
Foster City, California		94404
(Address of principal executive offices)		(Zip Code)

320 Hatch Drive
Foster City, California		94404
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (415) 851-2410

N/A

(Former name or former address, if changed since last report)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value NIS 0.35 each		NTBL		The Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.0205 ~~Departure~~Costs ofAssociated ~~Directors~~with Exit or ~~Certain~~Disposal ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Activities.

On September 1618, 2024, the Board of Directors of Notable Labs, Ltd. (the “Company” or “Notable”) ~~appointed~~approved ~~Kaile~~a A.streamlined operating ~~Zagger~~plan aswhich ~~its~~includes ~~Interim Chief~~exploring ~~Executive~~strategic ~~Officer~~alternatives ~~and~~focused ~~Chief~~on ~~Restructuring~~maximizing ~~Officer~~shareholder value.

~~Ms.~~In ~~Zagger,~~order ~~age~~to ~~44,~~conserve iscash ain ~~Managing~~connection ~~Director~~with ofthe ~~Province,~~streamlined ~~LLC~~operating plan, ~~and~~the ~~Chair~~Board of ~~its~~Directors ~~Healthcare~~also ~~Practice~~approved: ~~Group,~~(i) aimmediately ~~position she has held since March~~pausing ~~2024.~~the ~~She~~implementation ~~joined~~of ~~Province~~the ~~after~~planned ~~many~~Phase ~~years~~2 study of ~~service~~Volasertib in ~~the~~relapsed/refractory ~~distressed~~AML ~~healthcare~~(r/r ~~space.~~AML), ~~Ms.~~and ~~Zagger~~(ii) ~~served~~a asreduction ~~Chief~~in ~~Commercial~~the ~~Officer~~Company’s ofemployee ~~Minerva~~workforce ~~Surgical,~~and ~~Inc~~outside ~~(Nasdaq:~~consultants ~~UTRS)~~by ~~from~~approximately ~~January~~65%, ~~2023~~which ~~through~~the ~~March~~Company ~~2024.~~expects ~~Previously~~to ~~she~~substantially ~~served~~complete asby ~~Chief~~September ~~Executive Officer and a~~24, ~~member~~2024. ofThe ~~the~~Company ~~Board~~anticipates ofrecognizing ~~Directors~~approximately of$0.1 ~~Infinant~~million ~~Health~~in ~~from~~total ~~March~~charges ~~2022~~in ~~through~~connection ~~January~~with ~~2023.~~the ~~She~~reduction ~~also~~in ~~served~~force, aswhich costs ~~Chief~~are ~~Operating~~expected ~~Officer of~~to ~~Aspira~~be ~~Women’s~~substantially ~~Health~~recognized ~~Inc.~~in ~~(Nasdaq:~~the ~~AWH)~~third ~~from~~and ~~November~~fourth ~~2020~~quarters ~~through~~of ~~March 2022~~2024. ~~Prior~~These ~~thereto~~charges ~~she~~will ~~served~~consist asprimarily aof ~~Senior Vice President~~cash ofcharges ~~Change~~for ~~Healthcare~~termination ~~Inc~~benefits. ~~(Nasdaq:~~The ~~CHNG)~~charges ~~from~~the ~~August~~Company ~~2019~~expects ~~through~~to ~~November~~incur ~~2020.~~in ~~She~~connection ~~was~~with ~~previously~~this ~~employed~~reduction atin ~~other~~workforce ~~healthcare~~and ~~companies~~the implementation ~~including~~of ~~Phillips~~a ~~Healthtech,~~strategic ~~Intuitive~~alternatives ~~Surgical,~~process GEare ~~Healthcare~~subject ~~and~~to ~~St.~~a ~~Jude~~number ~~Medical~~of assumptions, risks and ~~has~~uncertainties, ~~over~~and 20actual ~~years~~results ofmay ~~experience~~materially differ. inThe ~~the~~Company ~~healthcare industry.~~may ~~Ms.~~also ~~Zagger~~incur ~~has~~other ~~led~~material ~~complex~~charges ~~transformations,~~not ~~re-organizations~~currently ~~and~~contemplated ~~commercial~~due ~~re-positions~~to inevents ~~the~~that ~~healthcare~~may ~~industry,~~occur ~~and~~as ~~navigated organizations~~a toresult ~~their~~of, ~~desired~~or associated ~~new~~with, ~~state~~these actions.

~~Ms.~~Forward-Looking ~~Zagger’s services are being provided to the Company by Province Fiduciary Services, LLC at an hourly rate of $900.~~Statements

~~Effective~~This ~~September~~report 16contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, ~~2024~~including but not limited to, Drexpress or implied statements regarding Notable’s strategic alternatives process; streamlined operating plan; the expected costs of the reduction in force and the timing of recognition of such charges; Notable’s future operations and goals; the potential benefits of any therapeutic candidates or platform technologies of Notable; the timing of any clinical milestones of Notable’s therapeutic candidates; the cash runway of the company; and other statements that are not historical fact. ~~Joseph~~All ~~Wagner~~statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and are based on the ~~Company~~then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Notable’s ~~Chief~~control. ~~Scientific~~Notable’s ~~Officer~~actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, ~~who~~including ~~was~~but ~~also~~not ~~acting~~limited to (i) uncertainties associated with Notable’s platform technologies, as ~~Chief~~well ~~Executive~~as ~~Officer~~risks onassociated with the clinical development and regulatory approval of product candidates, including potential delays in anthe ~~interim~~commencement, ~~basis~~enrollment and completion of clinical trials; (ii) risks related to the inability of Notable to obtain sufficient additional capital to continue to advance these product candidates and any preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) risks associated with Notable’s future financial and operating results, ~~stepped~~including ~~down~~its ability to become profitable; (vi) Notable’s ability to retain key personnel; (vii) Notable’s ability to manage the requirements of being a public company; (viii) uncertainties relating to the Israel-Hamas war; (ix) Notable’s ability to obtain orphan drug designation, and the associated benefits, for any of its drug candidates; (x) Notable’s inability to obtain regulatory approval for any of its drug candidates; and (xi) changes in, or additions to international, federal, state or local legislative requirements, such as changes in or additions to tax laws or rates, pharmaceutical regulations, and other regulations. Actual results and the timing of events could differ materially from ~~his~~those ~~position~~anticipated in such forward-looking statements as ~~interim~~a ~~Chief~~result ~~Executive~~of ~~Officer~~these risks and uncertainties. DrThese and other risks and uncertainties are more fully described in periodic filings with the U.S. ~~Wagner~~Securities ~~will~~and Exchange ~~continue~~Commission (“SEC”), including the factors described in ~~his~~the ~~role~~section titled “Risk Factors” in the Annual Report on Form 10-K of Notable Labs, Ltd. for the year ended December 31, 2023 as filed with the ~~Company’s~~SEC, and in other subsequent filings ~~Chief~~with ~~Scientific~~the ~~Officer~~SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Notable expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		NOTABLE LABS, LTD.	~~NOTABLE LABS, LTD.~~
Date:	September 16, 2024	By:	/s/ Scott A. McPherson
Date:September 19, 2024	By:	/s/ Kaile A. Zagger
	Name:	~~Name:~~Kaile A. Zagger	~~Scott A. McPherson~~
	Title:	~~Title:~~Chief Restructuring Officer and Interim Chief Executive Officer	~~Chief Financial Officer~~

Filing Compare · Notable Labs, Ltd.